Dicerna Pharmaceuticals, Inc. (DRNA) insider have most recently took part in a trading activity. On Dec 18, 2017 Bain Capital Life Sciences Investors, Llc, Director, 10% Owner bought 285,000 shares having total worth of $1,995,000 at the price of $7 per share, following the transaction a total of 8,930,237 shares owned by Bain Capital Life Sciences Investors, Llc.
Shares of Dicerna Pharmaceuticals, Inc. (DRNA) traded down 5.46% on Dec 18, 2017, hitting $7.18. 191,663 shares of the company’s stock traded hands. Dicerna Pharmaceuticals, Inc. has a 52 week low of $2.45 and a 52 week high of $9.84. The company’s market cap is $89 million.
Dicerna Pharmaceuticals, Inc. (DRNA) last announced its earnings results on Nov 2, 2017. The company reported -0.92 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.69 by $0.23. The company had revenue of $0 million for the quarter, compared to the consensus estimate of $0 million. During the same quarter in the previous year, the company posted -0.68 earnings per share. The company’s revenue for the quarter was up 193% on a year-over-year basis.
|earnings per share||-0.92||-0.86||-0.68||-0.68||-0.68||-0.75||-0.76||-0.76||-0.71||-0.72|
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018